Entrada Therapeutics (NASDAQ:TRDA – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports. They currently have ...
It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and regulatory updates were in focus. Recap of the Week’s ...
Hosted on MSN18h
Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDAIt was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and ...
In the phase 1/2 INSPIRE DUCHENNE trial, interim data showed an average microdystrophin expression of 110% among participants ...
The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback